Related Experiment Video
Updated: Jul 4, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Obstacles and solutions for implementing amyloid-targeting treatments in Europe
Anna Hofmann1,2, Robert Perneczky2,3,4,5,6,7
1Department of Neurology and Knight Alzheimer Disease Research Center Washington University St. Louis Missouri USA.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|July 3, 2026
Summary
New Alzheimer's disease (AD) therapies require major healthcare system updates in Europe. Modernizing early diagnosis and infrastructure is crucial for equitable patient access to these disease-modifying treatments.
Area of Science:
- Neurology
- Pharmacology
- Health Policy
Background:
- European Medicines Agency approvals signify a new era for Alzheimer's disease (AD) treatments.
- Disease-modifying therapies present significant challenges to European healthcare systems.
- Adaptation and modernization are essential for integrating novel AD treatments.
Purpose of the Study:
- To identify obstacles to implementing amyloid-targeting Alzheimer's disease treatments in Europe.
- To propose solutions for overcoming these implementation hurdles.
- To advocate for modernization of diagnostic and monitoring infrastructure.
Main Methods:
- Perspective article synthesizing current challenges and potential solutions.
- Analysis of diagnostic pathways, biomarker acceptance, and infrastructure limitations.
- Review of policy implications for novel Alzheimer's disease therapies.
Main Results:
- Key obstacles include delayed diagnosis, low adoption of new diagnostic tools (blood tests, digital screening), insufficient MRI capacity, and fragmented registries.
- Lack of early, biomarker-based diagnosis hinders timely treatment initiation.
- Fragmented infrastructure impedes effective monitoring and data collection.
Conclusions:
- Urgent, coordinated action is needed from clinicians, researchers, and policymakers.
- Modernizing diagnostic pathways and monitoring infrastructure is critical.
- Timely, safe, and equitable access to novel AD treatments requires systemic adaptation.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...